Actinium Announces Collaboration with Albert Einstein College of Medicine on New Actinium Program
Oct 27 14
Actinium Pharmaceuticals, Inc. announced collaboration with Albert Einstein College of Medicine on New Actinium Program. The company and Albert Einstein College of Medicine of Yeshiva University started development of an antibody construct labeled with actinium-225 using a novel technology that potentially allows for the expansion of use of the Company's proprietary platform and enables further manufacturing improvements of alpha therapy technology based drug candidates. The first antibody to be labeled using the new technology has potential to be broadly used in the field of hematology/oncology. Preclinical studies of the new technology have demonstrated significant improvements in product's manufacturing while maintaining biological integrity and properties of labeled antibodies. In addition to making the manufacturing process more time and cost efficient, the new technology allows for a greater versatility in adjusting the final constructs to various clinical situations. Clinical trials of drug candidates based on alpha emitting isotopes have already demonstrated significant efficacy with minimal side effects in blood borne cancers, in metastases of solid cancers and in residual disease in solid cancers post-surgery.
The Children's Hospital at Montefiore and Albert Einstein College of Medicine Appoints Betsy Herold as Chief of the Division of Pediatric Infectious Diseases
Jul 30 14
The Children’s Hospital at Montefiore (CHAM) and Albert Einstein College of Medicine of Yeshiva University have named Betsy Herold, M.D., chief, Division of Pediatric Infectious Diseases, CHAM and Einstein. She assumed her new position on July 1. Dr. Herold also serves as vice chair for research development in the Department of Pediatrics at CHAM and Einstein. She is a professor of Pediatrics, Microbiology and Immunology, and Obstetrics & Gynecology and Women’s Health and holds the Harold and Muriel Block Chair of Pediatrics at Einstein. Dr. Herold joined Montefiore and Einstein in 2007 after serving as the division chief of Pediatric Infectious Diseases at the former Mount Sinai School of Medicine. In her new role at Montefiore and Einstein, Dr. Herold will be responsible for continuing the expansion and further development of the Division of Pediatric Infectious Diseases’ clinical, translational and basic research efforts, and will oversee the Department’s educational missions. Most recently, Dr. Herold’s lab has concentrated on developing a vaccine for HSV in collaboration with William Jacobs, Jr., Ph.D., professor, Microbiology and Immunology, Einstein. Her lab also directs clinical trials to study strategies designed to protect women and babies from HSV and HIV, and basic and translational studies to determine how the two viruses interact with one another. In addition to her lab research, Dr. Herold also conducts clinical research related to the prevention of infectious disease complications in children who receive organ or bone marrow transplantation.
Albert Einstein College of Medicine Presents at BioPharm America 2013, Sep-19-2013 09:45 AM
Sep 17 13
Albert Einstein College of Medicine Presents at BioPharm America 2013, Sep-19-2013 09:45 AM. Venue: Westin Boston Waterfront Hotel, Boston, Massachusetts, United States.